Company Overview
Imunon, Inc. operates as a clinical-stage biotechnology company dedicated to the development of immunotherapies and vaccines, with its primary clinical focus on IMNN-001, a DNA-based immunotherapy designed for the localized treatment of ovarian cancer that is currently in Phase II clinical development. The company functions within the healthcare sector, specifically under the biotechnology industry, which typically involves high-risk, high-reward research and development activities aimed at creating novel medical treatments rather than generating immediate revenue from established product lines. As of the latest data, Imunon, Inc. holds a market capitalization of $9.25M and employs a workforce of 25 individuals, indicating a very early-stage enterprise with limited human capital dedicated to its operations. The combination of a sub-$10M market cap and the absence of reported annual revenue (N/A) signifies that the company is in a pre-commercialization phase where valuation is derived entirely from potential future clinical success and intellectual property rather than current sales performance.
Financial Health
The company reports a net income of $-14,329,403 and an EBITDA of $-14,281,106 over the trailing twelve months, while revenue figures are listed as N/A, suggesting that the gap between revenue and net income reflects significant operating expenses incurred during the research and development of its lead assets. These negative earnings metrics indicate that the company is burning cash to advance its clinical programs, a common characteristic of clinical-stage biotech firms, where the cost of running trials far exceeds any income generated from current operations. Free cash flow stands at $-9,282,318, which highlights the substantial cash outflow required to sustain daily operations and fund ongoing clinical trials, thereby limiting the company's immediate financial flexibility to return capital to shareholders or pay down debt without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for entities with no revenue, indicating that the company has not yet achieved the scale necessary to generate a positive contribution margin from sales. On the balance sheet, Imunon, Inc. holds $5.25M in cash against $1.10M in debt, resulting in a debt-to-equity ratio of 27.00, which suggests a relatively conservative leverage profile given the company's lack of revenue and negative earnings. The current ratio of 1.73 indicates that the company possesses $1.73 in current assets for every $1.00 of current liabilities, providing a buffer for short-term liquidity needs despite the lack of cash generation from operations. Return on equity is reported at -233.5% and return on assets at -77.7%, revealing that management effectiveness is currently measured by the rate of capital erosion rather than profit generation, as the negative returns are a direct consequence of the heavy investment in R&D without corresponding commercial output.
Valuation Assessment
Valuation multiples for Imunon, Inc. are distorted by its lack of earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -0.74, implying that traditional earnings-based valuation models are not applicable until the company achieves profitability. The price-to-book ratio is 1.93, indicating that the market values the company at nearly twice its book value, a premium that reflects the potential worth of its pipeline assets and intellectual property rather than its current financial standing. Alternative valuation metrics such as price-to-sales are N/A due to the absence of revenue, while the EV/EBITDA stands at -0.29, further confirming that the company is valued on a cash-flow-negative basis typical of pre-revenue biotechnology ventures. The stock has exhibited significant price volatility, with a 52-week high of $41.22 and a 52-week low of $2.64, creating a range of $38.58 where the current price sits relative to this historical span depending on market conditions at the time of observation. The beta value is 2.16, meaning the stock is expected to be approximately 116% more volatile than the broader market, a characteristic often seen in small-cap biotechnology stocks that react sharply to clinical trial results or sector-specific regulatory news.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, as neither metric currently exists to facilitate such an analysis. As a non-dividend payer, Imunon, Inc. has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the company retains all available capital to reinvest into its clinical programs rather than distributing income to shareholders. The absence of a dividend policy is consistent with the lifecycle of a clinical-stage company, where earnings are negative and any retained earnings are immediately consumed by operational burn rates rather than distributed. Consequently, the overall growth and income profile for Imunon, Inc. is characterized by zero current income generation and a reliance on external capital markets to fund future growth through the development of its immunotherapy and vaccine pipeline.